Genomic Health Inc (GHDX) Files Form 4 Insider Selling : G Bradley Cole Sells 5,000 Shares

Genomic Health Inc (GHDX): G Bradley Cole , COO of Genomic Health Inc sold 5,000 shares on Jun 9, 2016. The Insider selling transaction was reported by the company on Jun 13, 2016 to the Securities and Exchange Commission. The shares were sold at $26.91 per share for a total value of $133,118.25 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 8, 2016, James J Vaughn (Chief Commercial Officer) sold 1,997 shares at $28.00 per share price.On May 18, 2016, G Bradley Cole (COO) sold 5,000 shares at $27.60 per share price.Also, On May 12, 2016, Phillip G. Febbo (Chief Medical Officer) sold 6,324 shares at $27.66 per share price.On May 6, 2016, Steven Shak (Chief Scientific Officer) sold 10,000 shares at $25.43 per share price.

Shares of Genomic Health (GHDX) ended Friday, Jun 10, 2016 session in red amid volatile trading. The shares closed down -0.02 points or -0.08% at $26.18 with 1,86,996 shares getting traded. Post opening the session at $25.89, the shares hit an intraday low of $25.01 and an intraday high of $26.45 and the price vacillated in this range throughout the day. The company has a market cap of $864 M and the number of outstanding shares has been calculated to be 3,30,15,163 shares. The 52-week high of Genomic Health is $35.79 and the 52-week low is $20.05.

Genomic Health Money Flow Index Chart

Genomic Health Inc. is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company offers its Oncotype DX tests as a clinical laboratory service where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score which it calls a Recurrence Score for invasive breast cancer and colon cancer a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer. The Company’s Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR) in standard tumor pathology specimens to provide tumor-specific information or the oncotype of a tumor. Its offerings also include Oncotype DX Breast Cancer Test Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test.

Leave a Reply

Genomic Health - Is it time to Sell?

Top Brokerage Firms are advising their investors on Genomic Health. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.